Association between subthalamic nucleus deep brain stimulation and weight gain: Results of a case–control study

Strowd, Roy E.; Herco, Maja; Passmore-Griffin, Leah; Avery, Bradley; Haq, Ihtsham; Tatter, Stephen B.; Tate, Jessica; Siddiqui, Mustafa S.

doi:10.1016/j.clineuro.2015.11.002

Cited by 16 publications

(14 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On average, we identified increases in body mass during the entire period. The analysis revealed a significant body mass gain in 21/21 studies (100%) with complete data sets at the latest follow‐up . For these 21 studies, the overall pooled mean body mass gain was +5.71 kg (baseline weight, 73.25 kg; range of body mass gain, 1.30 kg ‐ 11.10 kg; 95% CI, ‐6,69, ‐4,74; N = 446; p < .0001; Figure ) with a corresponding effect size of d = 0.64 (Suppl.…”

Section: Resultsmentioning

confidence: 96%

“…The literature search identified 206 potentially relevant articles of which 154 studies were assessed for a more detailed evaluation (Figure ). Following the selection process, 54 studies fulfilled the inclusion criteria as described above. For the analysis, 38 studies could be included of which 18 (47%) were prospective case studies, 12 (32%) were prospective case‐control studies, 4 (11%) were retrospective case studies, 2 (5%) were retrospective case‐control studies, 1 (2.5%) was a cross‐sectional, and 1 (2.5%) was a retrospective survey study.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review of body mass gain after deep brain stimulation of the subthalamic nucleus in patients with Parkinson's disease

et al. 2019

View full text Add to dashboard Cite

This systematic review investigated the effects of deep brain stimulation of the subthalamic nucleus on extent and time course of body mass changes in patients with Parkinson's disease. A computerized search identified relevant articles using a priori defined inclusion and exclusion criteria. A descriptive analysis was calculated for the main outcome parameters body mass and BMI. Thirty-eight out of 206 studies fulfilled the inclusion criteria (979 patients aged 59.0±7.5 years). Considering the longest follow-up time for each study, body mass and BMI showed a mean increase across studies of +5.71kg (p < .0001; d = 0.64) and +1.8kg/m 2 (p < .0001; d = 1.61). The time course of body mass gain revealed a continuous increase ranging from +3.25kg (d = 0.69) at 3 months, +3.88kg (d = 0.21) at 6 months, +6.35kg (d = 0.72) at12 months, and +6.11kg (d = 1.02) greater than 12 months. Changes in BMI were associated with changes in disease severity (r = 0.502, p = .010) and pharmacological treatment (r = 0.440, p = .0231). Data suggest that body mass gain is one of the most common side effects of deep brain stimulation going beyond normalization of preoperative weight loss. Considering the negative health implications of overweight, we recommend the development of tailored therapies to prevent overweight and associated metabolic disorders following this treatment.

show abstract

Section: Resultsmentioning

confidence: 96%

Section: Resultsmentioning

confidence: 99%

A systematic review of body mass gain after deep brain stimulation of the subthalamic nucleus in patients with Parkinson's disease

et al. 2019

View full text Add to dashboard Cite

show abstract

“…83 In a recent retrospective case–control study, this same group reported a mean weight gain of 2.9 kg in the STN DBS group, significantly more than in the control group on BMT, with mean loss of 1.8 kg. 84 An early prospective study showed a 4.7 kg. increase in PD patients after surgery at 1-year follow-up.…”

Section: Dbs Effect On Body Weightmentioning

confidence: 99%

The effect of deep brain stimulation on the non-motor symptoms of Parkinson’s disease: a critical review of the current evidence

Kurtis

Rajah

Delgado

et al. 2017

npj Parkinson's Disease

118

View full text Add to dashboard Cite

The benefit of deep brain stimulation (DBS) in controlling the motor symptoms of Parkinson’s disease is well established, however, the impact on the non-motor symptoms (NMS) remains to be elucidated, although the growing investigative efforts are promising. This article reviews the reported data and considers the level of evidence available with regard to the effect of DBS on NMS total burden and on the cognitive, neuropsychiatric, sleep, pain, dysautonomic, and weight domains. Multiple case series suggest that DBS improves the burden of NMS by reducing prevalence, intensity, and non-motor fluctuations. There is level I evidence on the effect of DBS on cognition and mood. Slight cognitive decline has been reported in most class I studies, although the functional effect is probably minimal. Two randomized prospective studies reported no change in depression while improvement of anxiety has been reported by a class I trial. Prospective cohort studies point to improvement of hyperdopaminergic behaviors, such as impulse control disorders, while others report that hypodopaminergic states, like apathy, can appear after DBS. There is only class III evidence supporting the benefit of DBS on other NMS such as nocturnal sleep, pain, dysautonomia (urinary, gastrointestinal, cardiovascular, and sweating), and weight loss. Although preliminary results are promising, randomized prospectively controlled trials with NMS as primary end points are necessary to further explore the effect of DBS on these often invalidating symptoms and offer conclusions about efficacy.

show abstract

“…Disorders in body composition and reduction of its mass are not beneficial from the aspect of maintenance of the health of a patient suffering from PD; therefore, its monitoring and prevention are important [9,10]. The causes of weight loss in patients with PD are related , on the one hand, with the sole process of eating and weakening of appetite, and on the other hand -a change in muscle metabolism [11]. The patients' eating problems may result from difficulties with biting, chewing, swallowing, and difficulties with using cutlery resulting from tremor and muscle rigidity [12].…”

Section: Introductionmentioning

confidence: 99%

Body composition assessment by bioelectrical impedance analysis among patients treated with L-dopa for Parkinson’s disease

Wilczyński¹,

Półrola²

2018

View full text Add to dashboard Cite

Introduction: Among the consequences of Parkinson's disease are disorders in body composition and weight loss. Aim of the research: An analysis of body composition of patients with Parkinson's disease treated with L-dopa. Material and methods: A group of 32 patients was examined, including 26 (81.25%) females and 6 (18.75%) males. The study was conducted in the Laboratory for Posturology in the Institute of Physiotherapy at the faculty of Medicine and Medical Sciences, Jan Kochanowski University in Kielce. Body composition was assessed using bioelectrical impedance analysis, which consists of the evaluation of resistance to the flow of an electric current. Results and conclusions: The majority of body composition parameters remained within the normal ranges. The mean body mass index (BMI) index in patients with Parkinson' disease was 24.12 kg/m 2 and remained within the normal range. The metabolic age of patients was 42.34 years and was considerably lower than the calendar age-54.28 years. Highly significant differences were observed between males and females according to body height (Z = 3.7541; p = 0.0002), body weight (Z = 3.2592; p = 0.0011), fat mass (%) (Z = 3.1627; p = 0.0016), fat-free mass (kg) (Z = 3.7417; p = 0.0002), muscle mass (kg) (Z = 3.7421; p = 0.0002), visceral fat (Z = 1.9892; p = 0.0467), total body water (kg), total body water content (%) (Z = 3.7428; p = 0.0002), extracellular water (kg) (Z = 3.7448; p = 0.0002), intracellular fluid (kg) (Z = 3.7424; p = 0.0002), and the ratio of extracellular water to total body water (%) (Z = 2.9223; p = 0.0035). There were also significant positive correlations between metabolic age and the Overall Stability Index (r = 0.4057, p = 0.0212) and Front-Back Stability Index (r = 0.3507, p = 0.0490). Streszczenie Wprowadzenie: Jedną z konsekwencji choroby Parkinsona są zaburzenia składu ciała i redukcja jego masy. Cel pracy: Analiza składu ciała pacjentów z chorobą Parkinsona leczonych L-dopą. Materiał i metody: Przebadano grupę 32 osób, w tym 26 (81,25%) kobiet i 6 (18,75%) mężczyzn. Badanie wykonano w Laboratorium Posturologii w Instytucie Fizjoterapii na Wydziale Lekarskim i Nauk o Zdrowiu Uniwersytetu Jana Kochanowskiego w Kielcach. Skład ciała oceniano metodą impedancji bioelektrycznej. Wyniki i wnioski: Większość parametrów składu ciała badanych mieściła się w normie. Średni wskaźnik masy ciała (BMI) pacjentów z chorobą Parkinsona wynosił 24,12 kg/m 2. Wiek metaboliczny badanych wynosił 42,34 roku i był znacz nie niższy od wieku kalendarzowego-54,28 roku. Wysoce istotne różnice między kobietami a mężczyznami dotyczyły wysokości ciała (Z =

show abstract

Association between subthalamic nucleus deep brain stimulation and weight gain: Results of a case–control study

Cited by 16 publications

References 27 publications

A systematic review of body mass gain after deep brain stimulation of the subthalamic nucleus in patients with Parkinson's disease

A systematic review of body mass gain after deep brain stimulation of the subthalamic nucleus in patients with Parkinson's disease

The effect of deep brain stimulation on the non-motor symptoms of Parkinson’s disease: a critical review of the current evidence

Body composition assessment by bioelectrical impedance analysis among patients treated with L-dopa for Parkinson’s disease

Contact Info

Product

Resources

About